Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer

Phase 3
Completed
Conditions
Head and Neck Cancer
First Posted Date
2004-01-29
Last Posted Date
2018-07-09
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
359
Registration Number
NCT00003888
Locations

Institute of Oncology and Radiology of Serbia, Belgrade, Former Yugoslavia

🇫🇷

CHR de Besancon - Hopital Jean Minjoz, Besancon, France

🇫🇷

Centre Hospital Regional Universitaire de Limoges, Limoges, France

and more 41 locations

Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer

Phase 3
Completed
Conditions
Lung Cancer
First Posted Date
2004-01-23
Last Posted Date
2013-12-19
Lead Sponsor
London Lung Cancer Group
Target Recruit Count
398
Registration Number
NCT00003364
Locations
🇬🇧

Royal Sussex County Hospital, Brighton, England, United Kingdom

🇬🇧

Royal Free Hospital, Hampstead, London, England, United Kingdom

🇬🇧

Cookridge Hospital, Leeds, England, United Kingdom

and more 11 locations

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

First Posted Date
2004-01-23
Last Posted Date
2023-07-06
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
39
Registration Number
NCT00003298
Locations
🇺🇸

New England Medical Center Hospital, Boston, Massachusetts, United States

🇺🇸

CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado, United States

🇺🇸

Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 27 locations

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Phase 2
Active, not recruiting
Conditions
Head and Neck Cancer
Interventions
Drug: Docetaxel
Drug: OSI-774
Drug: Cisplatin
First Posted Date
2004-01-21
Last Posted Date
2024-07-05
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT00076310
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors

First Posted Date
2004-01-15
Last Posted Date
2021-02-23
Lead Sponsor
UNICANCER
Target Recruit Count
280
Registration Number
NCT00002566
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

Phase 2
Completed
Conditions
Head and Neck Cancer
Lung Cancer
First Posted Date
2004-01-14
Last Posted Date
2013-04-17
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
29
Registration Number
NCT00021333
Locations
🇺🇸

St. Francis Medical Center, Trenton, New Jersey, United States

🇺🇸

Southern Chester County Medical Center, West Grove, Pennsylvania, United States

🇺🇸

Kimball Medical Center, Lakewood, New Jersey, United States

and more 15 locations

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Phase 3
Completed
Conditions
Malignant Mesothelioma
First Posted Date
2004-01-13
Last Posted Date
2013-08-07
Lead Sponsor
Medical Research Council
Target Recruit Count
840
Registration Number
NCT00075699
Locations
🇬🇧

Royal Marsden NHS Foundation Trust - Surrey, Sutton, England, United Kingdom

🇬🇧

Leeds General Infirmary at Leeds Teaching Hospital NHS Trust, Leeds, England, United Kingdom

🇬🇧

Saint Bartholomew's Hospital, London, England, United Kingdom

Fluorouracil, Irinotecan, Leucovorin, and Cisplatin as First-Line Therapy in Treating Patients With Metastatic Esophageal Cancer

Phase 2
Conditions
Esophageal Cancer
First Posted Date
2004-01-13
Last Posted Date
2008-07-24
Lead Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Registration Number
NCT00075738
Locations
🇫🇷

Clinique La Casamance, Abugne, France

🇫🇷

Hopital Drevon, Dijon, France

🇫🇷

Centre Jean Bernard, Le Mans, France

and more 12 locations

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

First Posted Date
2004-01-08
Last Posted Date
2020-08-03
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
8
Registration Number
NCT00020787
Locations
🇺🇸

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer

Phase 2
Terminated
Conditions
Head and Neck Cancer
First Posted Date
2003-12-10
Last Posted Date
2022-01-26
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
35
Registration Number
NCT00003777
Locations
🇺🇸

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy